Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): A double-blind, single-dose, crossover study in healthy volunteers

BioDrugs

Volumn 26, Issue 3, 2012, Pages 177-184

  Yi, SoJeong ^a   Kim, Sung Eun ^a   Park, Min Kyu ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Lim, Kyoung Soo ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Bioequivalence; Comparative pharmacokinetics; Etanercept

Indexed keywords

BIOSIMILAR AGENT; ETANERCEPT; HD 203; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SKIN DISEASE; SORE THROAT;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84860619510     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11631860-000000000-00000     Document Type: Article

References (25)

1. Goffe B, Cather JC. Etanercept: An overview. JAmAcad Dermatol. 2003 Aug; 49 (2 Suppl.): S105-11
2. Public Health Service (PHS) Act in Section 262: Regulation of biological products [online]. Available from URL: http://www.fda.gov/Regulatory Information/Legislation/FederalFoodDrugandCosmeticActFDCAct/Signif icantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm [Accessed 2012 Mar 21]
3. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23 (1): 43-51
4. Seo KS, Yoon JW, Na KH, et al. Evaluation of process efficiency and bioequivalence of biosimilar recombinant human chorionic gonadotropin (rhCG). BioDrugs 2011; 25 (2): 115-27
5. Stanhope R, Sorgel F, Gravel P, et al. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. J Clin Pharmacol 2010 Nov; 50 (11): 1339-48
6. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011 May 12; 13 (3): 112
7. Investigator's Brochure of HD203. Seoul: Hanwha Chemical Co., 2010. (Data on file)
8. Hanwha Chemical. Safety and pharmacokinetic characteristics of HD203 in healthy male volunteers (SPH) [ClinicalTrials.gov identifier NCT01044836]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www/clinicaltrials.gov [Accessed 2012 Mar 21]
9. Adami HO, Rimsten A, Stenkvist B, et al. Influence of height, weight and obesity on risk of breast cancer in an unselected Swedish population. Br J Cancer 1977 Dec; 36 (6): 787-92
10. Quantikine (Human sTNF RII/TNFRSF1B Immunoassay) [package insert]. Minneapolis (MN): R&D Systems, Inc., 2010
11. Sullivan JT, Ni L, Sheelo C, et al. Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections. J Clin Pharmacol 2006 Jun; 46 (6): 654-61
12. Commitee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. European Medicines Agency, 2011 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Sci entific-guideline/2011/08/WC500109686.pdf [Accessed 2012 Mar 27]
13. Marzo A. Open questions on bioequivalence: some problems and some solutions. Pharmacol Res 1999 Oct; 40 (4): 357-68
14. Richens A. Proof of efficacy trials: cross-over versus parallel-group. Epilepsy Res 2001 May; 45 (1-3): 43-7; discussion 9-51
15. Anderson P, Louie J, Lau A, et al. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005 Mar; 7 (1): 3-9
16. Looper YJ. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics. Curr Opin Drug Discov Devel 2010 Mar; 13 (2): 247-56
17. Korea Food and Drug Administration. Guidelines on the evaluation of biosimilar products, 2009 Jul [online]. Available from URL: http://www.kfda. go.kr/index.kfda?mid=226 [Accessed 2012 Mar 21]
18. Zhou H, Parks V, Patat A, et al. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004 Nov; 44 (11): 1244-51
19. Zhou H, Patat A, Parks V, et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004 May; 44 (5): 543-50
20. Kawai S, Sekino H, Yamashita N, et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006 Apr; 46 (4): 418-23
21. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000 Feb; 34 (2): 161-4
22. Zhou SY, Shu C, Korth-Bradley J, et al. Integrated population pharmacokinetics of etanercept in healthy subjects and patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol 2011; 51 (6): 864-75
23. Fang Y, Li LJ, Wang R, et al. Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with ankylosing spondylitis. Acta Pharmacol Sin 2010 Nov; 31 (11): 1500-7
24. Zhou SY, Shu C, Korth-Bradley J, et al. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol 2011 Jun; 51 (6): 864-75
25. Hanwha Chemical. Randomized double-blind parallel trial to evaluate equivalence in efficacy and safety of HD203 and Enbrel in RA patients [Clinical- Trials.gov identifier NCT01270997]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www/clinicaltrials. gov [Accessed 2012 Mar 21]